Global Drugs for Vulvovaginal Candidiasis Market Research Report 2026

Drugs for Vulvovaginal Candidiasis Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Drugs for Vulvovaginal Candidiasis competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Drugs for vulvovaginal candidiasis are used to prevent and treat infections of the female vulva and vagina caused by Candida albicans and other Candida species. These drugs include topical formulations such as vaginal suppositories and gels, as well as systemic oral antifungals. They work by inhibiting fungal cell membrane synthesis or disrupting metabolic processes, providing rapid relief from symptoms such as itching, burning, and abnormal discharge, while reducing recurrence. Current development trends emphasize high selectivity, low toxicity, and combination therapies that regulate vaginal microecology to meet individualized patient needs. With increasing awareness of women’s health and improved access to healthcare, drugs for vulvovaginal candidiasis are becoming a significant segment of the global gynecological pharmaceutical market. In 2024, global Drugs for vulvovaginal candidiasis production reached approximately 354 m units, with an average global market price of around US$ 3.5 perunit.The average gross profit margin of this product is around 50%.

The market for drugs treating vulvovaginal candidiasis is driven by increased awareness of women’s health, expanded outpatient and community healthcare coverage, and supportive reproductive health policies. Annual reports of leading pharmaceutical companies indicate continued launches of new topical and systemic antifungal drugs, with improved formulations and administration routes enhancing patient adherence. Epidemiological data show recurrent infections and resistance issues prompting healthcare providers and patients to seek higher efficacy and safety, creating opportunities for innovative drugs and combination therapies. Growth in online pharmaceutical sales and telemedicine further diversifies product promotion and patient education channels, facilitating market penetration.Despite strong demand, the industry faces challenges such as stringent regulatory approvals, patent barriers, and price competition. New drug development requires lengthy cycles and high clinical validation costs, while differences in adverse reactions and patient adherence between topical and systemic therapies may affect market acceptance. In some emerging markets, uneven distribution of healthcare resources limits product accessibility. Additionally, increasing antifungal resistance may necessitate frequent adjustments in treatment protocols, adding R&D pressure and complexity to inventory management for pharmaceutical companies.Clinical demand is becoming more precise, personalized, and convenient. Patients and healthcare providers prefer short-course, fast-acting, low-side-effect therapies that can be combined with microecological regulation. Gynecological outpatient clinics, community healthcare centers, and online medical platforms have become key channels for sales and usage, promoting the development of convenient formulations such as vaginal gels and sustained-release suppositories, as well as digital management services. Going forward, personalized treatment, recurrence prevention, and microecological combination therapies will shape downstream demand, driving innovation in product portfolios and service models.Core raw materials for drugs treating vulvovaginal candidiasis include active antifungal ingredients (e.g., fluconazole, itraconazole, clotrimazole), pharmaceutical excipients (matrix materials, lubricants, sustained-release carriers), and packaging materials. Annual reports indicate that supply of high-purity active ingredients is concentrated, relying on stable international or domestic suppliers. Raw material price fluctuations, cross-border supply chains, and regulatory changes may affect production costs and delivery timelines. By establishing long-term partnerships, multi-source procurement, and optimized manufacturing processes, companies can ensure stable supply while controlling costs and supporting the development of new formulations and innovative combination therapy strategies.

This report delivers a comprehensive overview of the global Drugs for Vulvovaginal Candidiasis market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Drugs for Vulvovaginal Candidiasis. The Drugs for Vulvovaginal Candidiasis market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Drugs for Vulvovaginal Candidiasis market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Drugs for Vulvovaginal Candidiasis manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Drugs for Vulvovaginal Candidiasis Market Report

Chapter Outline

1.1 Product Definition

1.2 Drugs for Vulvovaginal Candidiasis by Type

1.2.1 Global Drugs for Vulvovaginal Candidiasis Market Value by Type: 2025 vs 2032

1.2.2 Cream

1.2.3 Pessary

1.2.4 Other

1.3 Drugs for Vulvovaginal Candidiasis by Application

1.3.1 Global Drugs for Vulvovaginal Candidiasis Market Value by Application: 2025 vs 2032

1.3.2 Hospital & Clinic

1.3.3 Pharmacy

1.4 Global Drugs for Vulvovaginal Candidiasis Market Size Estimates and Forecasts

1.4.1 Global Drugs for Vulvovaginal Candidiasis Revenue 2021–2032

1.4.2 Global Drugs for Vulvovaginal Candidiasis Sales 2021–2032

1.4.3 Global Drugs for Vulvovaginal Candidiasis Market Average Price (2021–2032)

1.5 Assumptions and Limitations

2.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturers (2021–2026)

2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Drugs for Vulvovaginal Candidiasis Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Drugs for Vulvovaginal Candidiasis, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Product Types and Applications

2.7 Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Date of Entry into the Industry

2.8 Global Drugs for Vulvovaginal Candidiasis Market Competitive Situation and Trends

2.8.1 Global Drugs for Vulvovaginal Candidiasis Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Drugs for Vulvovaginal Candidiasis Players Market Share by Revenue

2.8.3 Global Drugs for Vulvovaginal Candidiasis Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3.1 Global Drugs for Vulvovaginal Candidiasis Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2021–2032

3.2.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2021–2026

3.2.2 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2027–2032

3.3 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2021–2032

3.3.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2021–2026

3.3.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2027–2032

3.4 North America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country

3.4.1 North America Drugs for Vulvovaginal Candidiasis Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Drugs for Vulvovaginal Candidiasis Sales by Country (2021–2032)

3.4.3 North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2021–2032)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country

3.5.1 Europe Drugs for Vulvovaginal Candidiasis Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2021–2032)

3.5.3 Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Region

3.6.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2021–2032)

3.6.3 Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country

3.7.1 Latin America Drugs for Vulvovaginal Candidiasis Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2021–2032)

3.7.3 Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country

3.8.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2021–2032)

3.8.3 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2021–2032)

4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2021–2026)

4.1.2 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2027–2032)

4.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2021–2032)

4.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2021–2032)

4.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2021–2026)

4.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2027–2032)

4.2.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2021–2032)

4.3 Global Drugs for Vulvovaginal Candidiasis Price by Type (2021–2032)

5.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2021–2032)

5.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2021–2026)

5.1.2 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2027–2032)

5.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2021–2032)

5.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2021–2032)

5.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2021–2026)

5.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2027–2032)

5.2.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2021–2032)

5.3 Global Drugs for Vulvovaginal Candidiasis Price by Application (2021–2032)

6.1 Bayer

6.1.1 Bayer Company Information

6.1.2 Bayer Description and Business Overview

6.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Bayer Drugs for Vulvovaginal Candidiasis Product Portfolio

6.1.5 Bayer Recent Developments/Updates

6.2 Perrigo

6.2.1 Perrigo Company Information

6.2.2 Perrigo Description and Business Overview

6.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Product Portfolio

6.2.5 Perrigo Recent Developments/Updates

6.3 J & J

6.3.1 J & J Company Information

6.3.2 J & J Description and Business Overview

6.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 J & J Drugs for Vulvovaginal Candidiasis Product Portfolio

6.3.5 J & J Recent Developments/Updates

6.4 Pfizer

6.4.1 Pfizer Company Information

6.4.2 Pfizer Description and Business Overview

6.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Product Portfolio

6.4.5 Pfizer Recent Developments/Updates

6.5 Bristol-Myers Squibb

6.5.1 Bristol-Myers Squibb Company Information

6.5.2 Bristol-Myers Squibb Description and Business Overview

6.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Portfolio

6.5.5 Bristol-Myers Squibb Recent Developments/Updates

6.6 Effik

6.6.1 Effik Company Information

6.6.2 Effik Description and Business Overview

6.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 Effik Drugs for Vulvovaginal Candidiasis Product Portfolio

6.6.5 Effik Recent Developments/Updates

6.7 Teva

6.7.1 Teva Company Information

6.7.2 Teva Description and Business Overview

6.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 Teva Drugs for Vulvovaginal Candidiasis Product Portfolio

6.7.5 Teva Recent Developments/Updates

6.8 Sanofi

6.8.1 Sanofi Company Information

6.8.2 Sanofi Description and Business Overview

6.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Product Portfolio

6.8.5 Sanofi Recent Developments/Updates

6.9 Cisen Pharmaceutical

6.9.1 Cisen Pharmaceutical Company Information

6.9.2 Cisen Pharmaceutical Description and Business Overview

6.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Portfolio

6.9.5 Cisen Pharmaceutical Recent Developments/Updates

6.10 Kingyork Group

6.10.1 Kingyork Group Company Information

6.10.2 Kingyork Group Description and Business Overview

6.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue, and Gross Margin (2021–2026)

6.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Portfolio

6.10.5 Kingyork Group Recent Developments/Updates

6.11 Teva Pharmaceuticals

6.11.1 Teva Pharmaceuticals Company Information

6.11.2 Teva Pharmaceuticals Description and Business Overview

6.11.3 Teva Pharmaceuticals Drugs for Vulvovaginal Candidiasis Sales, Revenue, and Gross Margin (2021–2026)

6.11.4 Teva Pharmaceuticals Drugs for Vulvovaginal Candidiasis Product Portfolio

6.11.5 Teva Pharmaceuticals Recent Developments/Updates

6.12 Lupin Pharmaceuticals

6.12.1 Lupin Pharmaceuticals Company Information

6.12.2 Lupin Pharmaceuticals Description and Business Overview

6.12.3 Lupin Pharmaceuticals Drugs for Vulvovaginal Candidiasis Sales, Revenue, and Gross Margin (2021–2026)

6.12.4 Lupin Pharmaceuticals Drugs for Vulvovaginal Candidiasis Product Portfolio

6.12.5 Lupin Pharmaceuticals Recent Developments/Updates

6.13 Globela Pharma

6.13.1 Globela Pharma Company Information

6.13.2 Globela Pharma Description and Business Overview

6.13.3 Globela Pharma Drugs for Vulvovaginal Candidiasis Sales, Revenue, and Gross Margin (2021–2026)

6.13.4 Globela Pharma Drugs for Vulvovaginal Candidiasis Product Portfolio

6.13.5 Globela Pharma Recent Developments/Updates

6.14 Yuanda Medical

6.14.1 Yuanda Medical Company Information

6.14.2 Yuanda Medical Description and Business Overview

6.14.3 Yuanda Medical Drugs for Vulvovaginal Candidiasis Sales, Revenue, and Gross Margin (2021–2026)

6.14.4 Yuanda Medical Drugs for Vulvovaginal Candidiasis Product Portfolio

6.14.5 Yuanda Medical Recent Developments/Updates

6.15 Huarun Medical

6.15.1 Huarun Medical Company Information

6.15.2 Huarun Medical Description and Business Overview

6.15.3 Huarun Medical Drugs for Vulvovaginal Candidiasis Sales, Revenue, and Gross Margin (2021–2026)

6.15.4 Huarun Medical Drugs for Vulvovaginal Candidiasis Product Portfolio

6.15.5 Huarun Medical Recent Developments/Updates

7.1 Drugs for Vulvovaginal Candidiasis Industry Chain Analysis

7.2 Drugs for Vulvovaginal Candidiasis Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Drugs for Vulvovaginal Candidiasis Production Mode & Process Analysis

7.4 Drugs for Vulvovaginal Candidiasis Sales and Marketing

7.4.1 Drugs for Vulvovaginal Candidiasis Sales Channels

7.4.2 Drugs for Vulvovaginal Candidiasis Distributors

7.5 Drugs for Vulvovaginal Candidiasis Customer Analysis

8.1 Drugs for Vulvovaginal Candidiasis Industry Trends

8.2 Drugs for Vulvovaginal Candidiasis Market Drivers

8.3 Drugs for Vulvovaginal Candidiasis Market Challenges

8.4 Drugs for Vulvovaginal Candidiasis Market Restraints

8.5 Impact of U.S. Tariffs

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

List of Tables

 Table 1. Global Drugs for Vulvovaginal Candidiasis Market Value by Type (US$ Million), 2025 vs 2032

 Table 2. Global Drugs for Vulvovaginal Candidiasis Market Value by Application (US$ Million), 2025 vs 2032

 Table 3. Global Drugs for Vulvovaginal Candidiasis Market Competitive Situation by Manufacturers in 2025

 Table 4. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) of Key Manufacturers (2021–2026)

 Table 5. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturers (2021–2026)

 Table 6. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Manufacturers (2021–2026)

 Table 7. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturers (2021–2026)

 Table 8. Global Market Drugs for Vulvovaginal Candidiasis Average Price (USD/Unit) of Key Manufacturers (2021–2026)

 Table 9. Global Key Players of Drugs for Vulvovaginal Candidiasis, Industry Ranking, 2023 vs 2024 vs 2025

 Table 10. Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Manufacturing Sites and Headquarters

 Table 11. Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Product Types and Applications

 Table 12. Global Key Manufacturers of Drugs for Vulvovaginal Candidiasis, Date of Entry into the Industry

 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

 Table 14. Global Drugs for Vulvovaginal Candidiasis Companies by Tier (Tier 1, Tier 2, Tier 3), based on Drugs for Vulvovaginal Candidiasis Revenue, 2025

 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

 Table 16. Global Drugs for Vulvovaginal Candidiasis Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

 Table 17. Global Drugs for Vulvovaginal Candidiasis Sales by Region (K Units), 2021–2026

 Table 18. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2021–2026)

 Table 19. Global Drugs for Vulvovaginal Candidiasis Sales by Region (K Units), 2027–2032

 Table 20. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2027–2032)

 Table 21. Global Drugs for Vulvovaginal Candidiasis Revenue by Region (US$ Million), 2021–2026

 Table 22. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2021–2026)

 Table 23. Global Drugs for Vulvovaginal Candidiasis Revenue by Region (US$ Million), 2027–2032

 Table 24. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2027–2032)

 Table 25. North America Drugs for Vulvovaginal Candidiasis Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 26. North America Drugs for Vulvovaginal Candidiasis Sales by Country (K Units), 2021–2026

 Table 27. North America Drugs for Vulvovaginal Candidiasis Sales by Country (K Units), 2027–2032

 Table 28. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (US$ Million), 2021–2026

 Table 29. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (US$ Million), 2027–2032

 Table 30. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 31. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (K Units), 2021–2026

 Table 32. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (K Units), 2027–2032

 Table 33. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (US$ Million), 2021–2026

 Table 34. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (US$ Million), 2027–2032

 Table 35. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

 Table 36. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (K Units), 2021–2026

 Table 37. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (K Units), 2027–2032

 Table 38. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (US$ Million), 2021–2026

 Table 39. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (US$ Million), 2027–2032

 Table 40. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 41. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (K Units), 2021–2026

 Table 42. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (K Units), 2027–2032

 Table 43. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (US$ Million), 2021–2026

 Table 44. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (US$ Million), 2027–2032

 Table 45. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 46. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (K Units), 2021–2026

 Table 47. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (K Units), 2027–2032

 Table 48. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (US$ Million), 2021–2026

 Table 49. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (US$ Million), 2027–2032

 Table 50. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2021–2026)

 Table 51. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2027–2032)

 Table 52. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2021–2026)

 Table 53. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2027–2032)

 Table 54. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Type (2021–2026)

 Table 55. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Type (2027–2032)

 Table 56. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2021–2026)

 Table 57. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2027–2032)

 Table 58. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Type (2021–2026)

 Table 59. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Type (2027–2032)

 Table 60. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2021–2026)

 Table 61. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2027–2032)

 Table 62. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2021–2026)

 Table 63. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2027–2032)

 Table 64. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Application (2021–2026)

 Table 65. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Application (2027–2032)

 Table 66. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2021–2026)

 Table 67. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2027–2032)

 Table 68. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Application (2021–2026)

 Table 69. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Application (2027–2032)

 Table 70. Bayer Company Information

 Table 71. Bayer Description and Business Overview

 Table 72. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

 Table 73. Bayer Drugs for Vulvovaginal Candidiasis Product

 Table 74. Bayer Recent Developments/Updates

 Table 75. Perrigo Company Information

 Table 76. Perrigo Description and Business Overview

 Table 77. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

 Table 78. Perrigo Drugs for Vulvovaginal Candidiasis Product

 Table 79. Perrigo Recent Developments/Updates

 Table 80. J & J Company Information

 Table 81. J & J Description and Business Overview

 Table 82. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

 Table 83. J & J Drugs for Vulvovaginal Candidiasis Product

 Table 84. J & J Recent Developments/Updates

 Table 85. Pfizer Company Information

 Table 86. Pfizer Description and Business Overview

 Table 87. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

 Table 88. Pfizer Drugs for Vulvovaginal Candidiasis Product

 Table 89. Pfizer Recent Developments/Updates

 Table 90. Bristol-Myers Squibb Company Information

 Table 91. Bristol-Myers Squibb Description and Business Overview

 Table 92. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

 Table 93. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product

 Table 94. Bristol-Myers Squibb Recent Developments/Updates

 Table 95. Effik Company Information

 Table 96. Effik Description and Business Overview

 Table 97. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

 Table 98. Effik Drugs for Vulvovaginal Candidiasis Product

 Table 99. Effik Recent Developments/Updates

 Table 100. Teva Company Information

 Table 101. Teva Description and Business Overview

 Table 102. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

 Table 103. Teva Drugs for Vulvovaginal Candidiasis Product

 Table 104. Teva Recent Developments/Updates

 Table 105. Sanofi Company Information

 Table 106. Sanofi Description and Business Overview

 Table 107. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

 Table 108. Sanofi Drugs for Vulvovaginal Candidiasis Product

 Table 109. Sanofi Recent Developments/Updates

 Table 110. Cisen Pharmaceutical Company Information

 Table 111. Cisen Pharmaceutical Description and Business Overview

 Table 112. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

 Table 113. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product

 Table 114. Cisen Pharmaceutical Recent Developments/Updates

 Table 115. Kingyork Group Company Information

 Table 116. Kingyork Group Description and Business Overview

 Table 117. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

 Table 118. Kingyork Group Drugs for Vulvovaginal Candidiasis Product

 Table 119. Kingyork Group Recent Developments/Updates

 Table 120. Teva Pharmaceuticals Company Information

 Table 121. Teva Pharmaceuticals Description and Business Overview

 Table 122. Teva Pharmaceuticals Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

 Table 123. Teva Pharmaceuticals Drugs for Vulvovaginal Candidiasis Product

 Table 124. Teva Pharmaceuticals Recent Developments/Updates

 Table 125. Lupin Pharmaceuticals Company Information

 Table 126. Lupin Pharmaceuticals Description and Business Overview

 Table 127. Lupin Pharmaceuticals Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

 Table 128. Lupin Pharmaceuticals Drugs for Vulvovaginal Candidiasis Product

 Table 129. Lupin Pharmaceuticals Recent Developments/Updates

 Table 130. Globela Pharma Company Information

 Table 131. Globela Pharma Description and Business Overview

 Table 132. Globela Pharma Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

 Table 133. Globela Pharma Drugs for Vulvovaginal Candidiasis Product

 Table 134. Globela Pharma Recent Developments/Updates

 Table 135. Yuanda Medical Company Information

 Table 136. Yuanda Medical Description and Business Overview

 Table 137. Yuanda Medical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

 Table 138. Yuanda Medical Drugs for Vulvovaginal Candidiasis Product

 Table 139. Yuanda Medical Recent Developments/Updates

 Table 140. Huarun Medical Company Information

 Table 141. Huarun Medical Description and Business Overview

 Table 142. Huarun Medical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

 Table 143. Huarun Medical Drugs for Vulvovaginal Candidiasis Product

 Table 144. Huarun Medical Recent Developments/Updates

 Table 145. Key Raw Materials Lists

 Table 146. Raw Materials Key Suppliers Lists

 Table 147. Drugs for Vulvovaginal Candidiasis Distributors List

 Table 148. Drugs for Vulvovaginal Candidiasis Customers List

 Table 149. Drugs for Vulvovaginal Candidiasis Market Trends

 Table 150. Drugs for Vulvovaginal Candidiasis Market Drivers

 Table 151. Drugs for Vulvovaginal Candidiasis Market Challenges

 Table 152. Drugs for Vulvovaginal Candidiasis Market Restraints

 Table 153. Research Programs/Design for This Report

 Table 154. Key Data Information from Secondary Sources

 Table 155. Key Data Information from Primary Sources

 Table 156. Authors List of This Report

List of Figures

 Figure 1. Product Picture of Drugs for Vulvovaginal Candidiasis

 Figure 2. Global Drugs for Vulvovaginal Candidiasis Market Value by Type (US$ Million), 2021–2032

 Figure 3. Global Drugs for Vulvovaginal Candidiasis Market Share by Type: 2025 & 2032

 Figure 4. Cream Product Picture

 Figure 5. Pessary Product Picture

 Figure 6. Other Product Picture

 Figure 7. Global Drugs for Vulvovaginal Candidiasis Market Value by Application (US$ Million), 2021–2032

 Figure 8. Global Drugs for Vulvovaginal Candidiasis Market Share by Application: 2025 & 2032

 Figure 9. Hospital & Clinic

 Figure 10. Pharmacy

 Figure 11. Global Drugs for Vulvovaginal Candidiasis Revenue, (US$ Million), 2021 vs 2025 vs 2032

 Figure 12. Global Drugs for Vulvovaginal Candidiasis Market Size (US$ Million), 2021–2032

 Figure 13. Global Drugs for Vulvovaginal Candidiasis Sales (K Units), 2021–2032

 Figure 14. Global Drugs for Vulvovaginal Candidiasis Average Price (USD/Unit), 2021–2032

 Figure 15. Drugs for Vulvovaginal Candidiasis Report Years Considered

 Figure 16. Drugs for Vulvovaginal Candidiasis Sales Share by Manufacturers in 2025

 Figure 17. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturers in 2025

 Figure 18. Top 5 and Top 10 Global Drugs for Vulvovaginal Candidiasis Players: Market Share by Revenue in Drugs for Vulvovaginal Candidiasis in 2025

 Figure 19. Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

 Figure 20. Global Drugs for Vulvovaginal Candidiasis Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

 Figure 21. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2021–2032)

 Figure 22. North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2021–2032)

 Figure 23. U.S. Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 24. Canada Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 25. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2021–2032)

 Figure 26. Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2021–2032)

 Figure 27. Germany Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 28. France Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 29. U.K. Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 30. Italy Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 31. Russia Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 32. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2021–2032)

 Figure 33. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2021–2032)

 Figure 34. China Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 35. Japan Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 36. South Korea Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 37. India Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 38. Australia Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 39. China Taiwan Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 40. Indonesia Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 41. Thailand Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 42. Malaysia Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 43. Philippines Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 44. Latin America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2021–2032)

 Figure 45. Latin America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2021–2032)

 Figure 46. Mexico Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 47. Brazil Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 48. Argentina Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 49. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2021–2032)

 Figure 50. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2021–2032)

 Figure 51. Turkey Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 52. Saudi Arabia Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 53. U.A.E Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (US$ Million), 2021–2032

 Figure 54. Global Sales Market Share of Drugs for Vulvovaginal Candidiasis by Type (2021–2032)

 Figure 55. Global Revenue Market Share of Drugs for Vulvovaginal Candidiasis by Type (2021–2032)

 Figure 56. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Type (2021–2032)

 Figure 57. Global Sales Market Share of Drugs for Vulvovaginal Candidiasis by Application (2021–2032)

 Figure 58. Global Revenue Market Share of Drugs for Vulvovaginal Candidiasis by Application (2021–2032)

 Figure 59. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Application (2021–2032)

 Figure 60. Drugs for Vulvovaginal Candidiasis Value Chain

 Figure 61. Channels of Distribution (Direct Vs Distribution)

 Figure 62. Bottom-up and Top-down Approaches for This Report

 Figure 63. Data Triangulation

 Figure 64. Key Executives Interviewed